Lipofundin Mct/Lct (Soya-Bean Oil Refined, Triglycerides, Medium Chain)

The formulation supplies triglycerides that are hydrolyzed by plasma lipases after infusion. The resulting free fatty acids are taken up by cells for energy production via β‑oxidation and for synthesis of phospholipids. Medium‑chain fatty acids are rapidly oxidized, while the long‑chain soybean fatty acids deliver essential linoleic and α‑linolenic acids needed for membrane integrity.

The prescribed dose of Lipofundin Mct/Lct is individualized by the treating clinician based on the patient’s caloric requirements, body weight, metabolic status, and laboratory monitoring of triglyceride levels. No fixed regimen is provided; the prescriber calculates the infusion rate to meet specific nutritional goals.

Safety data for Lipofundin Mct/Lct in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Use is generally reserved for situations where the benefit to the mother outweighs potential risks to the fetus or infant, and it should be prescribed only after careful clinical assessment.

To place an order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain where applicable) and any necessary import documentation.

Lipofundin Mct/Lct combines soybean oil with medium‑chain triglycerides, offering a balanced profile of long‑chain essential fatty acids and rapidly oxidizable medium‑chain fats. Compared with pure soybean‑oil emulsions, it may result in lower triglyceride accumulation and provides quicker energy availability, while still meeting essential fatty acid requirements.

The emulsion should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, inspect the container for any signs of separation or discoloration. Keep the product in its original packaging until administration to maintain sterility and stability.

Lipofundin Mct/Lct is administered intravenously as an emulsion infusion, typically via a dedicated lumen or filter set to prevent lipid buildup. The infusion rate is set by the prescriber based on the patient’s nutritional plan and monitored regularly for tolerance and serum triglyceride levels.

Serious risks include fat overload syndrome, which can lead to organ dysfunction, and severe allergic reactions such as anaphylaxis. Rarely, lipid embolism or pulmonary complications may occur. Prompt recognition of symptoms and immediate medical intervention are essential to mitigate these risks.

Patients with known hypersensitivity to soy, egg phospholipids, or any component of the emulsion should not receive Lipofundin Mct/Lct. It is also contraindicated in individuals with severe hypertriglyceridemia, uncontrolled lipid metabolism disorders, or those who have experienced previous severe reactions to intravenous lipid emulsions.